{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05355701",
            "orgStudyIdInfo": {
                "id": "C4761001"
            },
            "secondaryIdInfos": [
                {
                    "id": "BRAF Class 2",
                    "type": "OTHER",
                    "domain": "Alias Study Number"
                }
            ],
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.",
            "officialTitle": "A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-to-learn-about-the-study-medicine-called-pf-in-people-with-advanced-solid-tumors-with-braf-alterations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08-13",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-02-13",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-26",
            "studyFirstSubmitQcDate": "2022-04-26",
            "studyFirstPostDateStruct": {
                "date": "2022-05-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors.\n\nThis study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called \"BRAF\" and available treatments are no longer effective in controlling their cancer.\n\nAll participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine:\n\n* People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day.\n* People with colorectal cancer may also receive cetuximab. Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV).\n\nParticipants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic."
        },
        "conditionsModule": {
            "conditions": [
                "Melanoma",
                "Non-Small-Cell Lung Cancer",
                "Thyroid Cancer",
                "Glioma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 156,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy dose escalation (Part 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07799933",
                    "interventionNames": [
                        "Drug: PF-07799933"
                    ]
                },
                {
                    "label": "Combination dose escalation (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07799933 in combination with binimetinib or cetuximab",
                    "interventionNames": [
                        "Drug: PF-07799933",
                        "Drug: binimetinib",
                        "Biological: cetuximab"
                    ]
                },
                {
                    "label": "Dose expansion (Part 3) - Tumor and mutation specific Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07799933",
                    "interventionNames": [
                        "Drug: PF-07799933"
                    ]
                },
                {
                    "label": "Dose expansion (Part 3) - Tumor and mutation specific Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive PF-07799933",
                    "interventionNames": [
                        "Drug: PF-07799933",
                        "Drug: binimetinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PF-07799933",
                    "description": "Tablet",
                    "armGroupLabels": [
                        "Combination dose escalation (Part 2)",
                        "Dose expansion (Part 3) - Tumor and mutation specific Cohort 1",
                        "Dose expansion (Part 3) - Tumor and mutation specific Cohort 2",
                        "Monotherapy dose escalation (Part 1)"
                    ],
                    "otherNames": [
                        "ARRY-440"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "binimetinib",
                    "description": "Tablet",
                    "armGroupLabels": [
                        "Combination dose escalation (Part 2)",
                        "Dose expansion (Part 3) - Tumor and mutation specific Cohort 2"
                    ],
                    "otherNames": [
                        "Mektovi, PF-06811462, MEK162"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "cetuximab",
                    "description": "Injection for intravenous use",
                    "armGroupLabels": [
                        "Combination dose escalation (Part 2)"
                    ],
                    "otherNames": [
                        "Erbitux"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)",
                    "description": "DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib or cetuximab",
                    "timeFrame": "Cycle 1 (21 days)"
                },
                {
                    "measure": "Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2)",
                    "description": "AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy",
                    "timeFrame": "Baseline to 28 days after last dose of study medication"
                },
                {
                    "measure": "Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2)",
                    "description": "Laboratory abnormalities as characterized by type, frequency, severity, and timing",
                    "timeFrame": "Baseline to 28 days after last dose of study treatment"
                },
                {
                    "measure": "Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2)",
                    "description": "Vital sign abnormalities as characterized by type, frequency, severity, and timing",
                    "timeFrame": "Baseline to 28 days after last dose of study treatment"
                },
                {
                    "measure": "Dose interruptions due to AEs (Part 1 and Part 2)",
                    "description": "Incidence of dose interruptions due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Dose dose modifications due to AEs (Part 1 and Part 2)",
                    "description": "Incidence of dose modifications due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Discontinuations due to AEs (Part 1 and Part 2)",
                    "description": "Incidence of discontinuations due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "MTD (Part 1 and Part 2)",
                    "description": "Maximum tolerated dose (MTD)",
                    "timeFrame": "Cycle 1 (21 days)"
                },
                {
                    "measure": "RDE (Part 1 and Part 2)",
                    "description": "Recommended dose for expansion (RDE)",
                    "timeFrame": "Cycle 1 (21 days)"
                },
                {
                    "measure": "Overall response rate (ORR) (Part 3)",
                    "description": "Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Number of participants with clinically significant physical exam abnormalities (Part 1 and Part 2)",
                    "description": "Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0",
                    "timeFrame": "Baseline to 28 days after last dose of study treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1 and Part 2: ORR",
                    "description": "ORR as assessed using the RECIST version 1.1.",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: Intracranial response",
                    "description": "Intracranial response by RECIST version 1.1 (for brain metastases) \\& Response Assessment in Neuro-Oncology (RANO) - for primary brain tumors).",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1 and Part 2: Duration of response",
                    "description": "Duration of response",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Number of participants with treatment-emergent adverse events (AEs)",
                    "description": "AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Number of participants with clinically significant change from baseline in laboratory abnormalities",
                    "description": "Laboratory abnormalities as characterized by type, frequency, severity, and timing",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Number of participants with clinically significant change from baseline in vital sign abnormalities",
                    "description": "Vital sign abnormalities as characterized by type, frequency, severity, and timing",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Dose interruptions due to AEs",
                    "description": "Incidence of dose interruptions due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Dose dose modifications due to AEs",
                    "description": "Incidence of dose modifications due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Discontinuations due to AEs",
                    "description": "Incidence of discontinuations due to AEs",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Time to event endpoints in each combination",
                    "description": "Time to event endpoints in each combination",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: Disease Control Rate (DCR)",
                    "description": "DCR",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, maximum observed concentration (Cmax)",
                    "description": "PK parameters of PF-07799933, Single dose, Cmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, time to maximum plasma concentration (Tmax)",
                    "description": "PK parameters of PF-07799933, Single dose, Tmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast)",
                    "description": "PK parameters of PF-07799933, Single dose, AUClast",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 24 hours (AUC24)",
                    "description": "PK parameters of PF-07799933, Single dose, AUC24",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 48 hours (AUC48)",
                    "description": "PK parameters of PF-07799933, Single dose, AUC48",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, terminal elimination half life (t\u00bd)",
                    "description": "PK parameters of PF-07799933, Single dose, t\u00bd",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf)",
                    "description": "PK parameters of PF-07799933, Single dose, AUCinf",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent oral clearance (CL/F)",
                    "description": "PK parameters of PF-07799933, Single dose, CL/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent volume of distribution (Vz/F)",
                    "description": "PK parameters of PF-07799933, Single dose, Vz/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, maximum observed concentration (Cmax)",
                    "description": "PK parameters of PF-07799933, Multiple dose, Cmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, trough plasma or serum concentration (Ctrough)",
                    "description": "PK parameters of PF-07799933, Multiple dose, Ctrough",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, time to maximum plasma concentration (Tmax)",
                    "description": "PK parameters of PF-07799933, Multiple dose, Tmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUC\u03c4)",
                    "description": "PK parameters of PF-07799933, Multiple dose, AUC\u03c4",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, CL/F",
                    "description": "PK parameters of PF-07799933, Multiple dose, CL/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, average plasma concentration (Cav)",
                    "description": "PK parameters of PF-07799933, Multiple dose, Cav",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, peak-to-trough ratio (PTR)",
                    "description": "PK parameters of PF-07799933, Multiple dose, PTR",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, accumulation ratio (Rac)",
                    "description": "PK parameters of PF-07799933, Multiple dose, Rac (AUC\u03c4 /AUCsd,\u03c4)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, t1/2",
                    "description": "PK parameters of PF-07799933, Multiple dose, t1/2",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 1/2/3: PK parameters of PF-07799933, Multiple dose, Vz/F",
                    "description": "PK parameters of PF-07799933, Multiple dose, Vz/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of cytochrome P450 (CYP)3A4 probe substrate midazolam, Cmax",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, Cmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, Tmax",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, Tmax",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUClast",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, AUClast",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, t\u00bd",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, t\u00bd",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUCinf",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, AUCinf",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, CL/F",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, CL/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PK parameters of CYP3A4 probe substrate midazolam, Vz/F",
                    "description": "PK parameters of CYP3A4 probe substrate midazolam, Vz/F",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: TTR",
                    "description": "Time to response (TTR)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: DOR",
                    "description": "Duration of response (DOR)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: PFS",
                    "description": "Progression-free survival (PFS)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Part 3: OS",
                    "description": "Overall survival (OS)",
                    "timeFrame": "Baseline to 2 years"
                },
                {
                    "measure": "Number of participants with clinically significant physical exam abnormalities (Part 3)",
                    "description": "Physical exam abnormalities as as graded by NCI CTCAE version 5.0",
                    "timeFrame": "Baseline to 28 days after last dose of study medication"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "This study is seeking participants who meet the following eligibility criteria:\n\nInclusion Criteria:\n\n* Diagnosis of advanced/metastatic solid tumor including primary brain tumor.\n* Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid \\[DNA\\], or ctDNA).\n* Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1 and Part 2).\n* Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies\n\nExclusion Criteria:\n\n* Brain metastasis larger than 4 cm\n* Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\n* For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "16 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Highlands Oncology Group",
                    "status": "RECRUITING",
                    "city": "Fayetteville",
                    "state": "Arkansas",
                    "zip": "72703",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.06258,
                        "lon": -94.15743
                    }
                },
                {
                    "facility": "Highlands Oncology Group",
                    "status": "RECRUITING",
                    "city": "Rogers",
                    "state": "Arkansas",
                    "zip": "72758",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.33202,
                        "lon": -94.11854
                    }
                },
                {
                    "facility": "Highlands Oncology Group",
                    "status": "RECRUITING",
                    "city": "Springdale",
                    "state": "Arkansas",
                    "zip": "72762",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.18674,
                        "lon": -94.12881
                    }
                },
                {
                    "facility": "Clinical and Translational Research Center (CTRC)",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Clinical And Translational Research Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "UCHealth Sue Anschutz-Rodgers Eye Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Colorado Anschutz Medical Campus",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Miami Hospital and Clinics, Sylvester Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "University of Miami Hospital and Clinics, Sylvester Cancer Center",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "DFCI Chestnut Hill",
                    "status": "RECRUITING",
                    "city": "Newton",
                    "state": "Massachusetts",
                    "zip": "02459",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33704,
                        "lon": -71.20922
                    }
                },
                {
                    "facility": "Brigitte Harris Cancer Pavilion",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Henry Ford Hospital",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Henry Ford Medical Center - Columbus",
                    "status": "RECRUITING",
                    "city": "Novi",
                    "state": "Michigan",
                    "zip": "48377",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.48059,
                        "lon": -83.47549
                    }
                },
                {
                    "facility": "MSK Monmouth",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "MSK David H. Koch Center for Cancer Care",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center 53rd street",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10022",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic Taussig Cancer Center Investigational Pharmacy",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Cleveland Clinic Taussing Cancer Center Investigational Pharmacy",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Providence Cancer Institute Franz Clinic",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97213",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Providence Portland Medical Center",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97213",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute - Pharmacy",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Tennessee Oncology PLLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Tennessee Oncology, PLLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "TriStar Bone Marrow Transplant",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "TriStar Centennial Medical Center - Cell Processing Lab",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "TriStar Centennial Medical center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START)",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Cross Cancer Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "The Ottawa Hospital - General Campus",
                    "status": "RECRUITING",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Jewish General Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "McGill University Health Centre",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Rabin Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Petah Tikva",
                    "state": "Hamerkaz",
                    "zip": "4941492",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "Sheba Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ramat Gan",
                    "state": "Hamerkaz",
                    "zip": "5265601",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Sourasky Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Tel Aviv, Yaffo",
                    "state": "Hamerkaz",
                    "zip": "6423906",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "Sourasky Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Tel Aviv",
                    "state": "Tell Ab\u012bb",
                    "zip": "6423906",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "Hadassah Medical Center",
                    "status": "RECRUITING",
                    "city": "Jerusalem",
                    "state": "Yerushalayim",
                    "zip": "9112001",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Rambam Health Care Campus",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Haifa",
                    "state": "\u1e24eif\u0101",
                    "zip": "3109601",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=C4761001"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013964",
                    "term": "Thyroid Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000013959",
                    "term": "Thyroid Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16718",
                    "name": "Thyroid Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16723",
                    "name": "Thyroid Neoplasms",
                    "asFound": "Thyroid Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}